William Blair Investment Management Boosts Stake in Vericel Corporation

The investment firm increased its holdings in the biotechnology company by over 90% in the third quarter.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

William Blair Investment Management LLC boosted its stake in shares of Vericel Corporation (NASDAQ:VCEL) by 90.3% during the third quarter, according to a recent SEC filing. The firm now owns 2,210,929 shares of the biotechnology company's stock, representing a 4.37% ownership stake worth $69,578,000.

Why it matters

Vericel is a leading regenerative medicine company focused on developing and commercializing cell-based therapies to repair damaged tissues and restore function. The significant increase in William Blair's investment suggests the firm sees strong growth potential in Vericel's business and product pipeline.

The details

According to the filing, William Blair Investment Management acquired an additional 1,048,864 shares of Vericel during the third quarter, bringing its total holdings to over 2.2 million shares. This represents a 90.3% increase in the firm's stake in the biotechnology company.

  • The filing covers the third quarter of 2026.

The players

William Blair Investment Management LLC

An investment management firm that provides a range of investment solutions to institutional and individual investors.

Vericel Corporation

A biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions.

Got photos? Submit your photos here. ›

The takeaway

William Blair's significant increase in its Vericel holdings suggests the investment firm sees strong long-term growth potential in the biotechnology company's regenerative medicine products and pipeline. This vote of confidence from a major institutional investor could signal positive things to come for Vericel.